Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Comparative Study Evaluating the Impact of Intensive Dietary Care on Weight Change and Biological Parameters in Patients Who Underwent Surgery for Craniopharyngioma During the First Postoperative Year (CRANIODIET)

18 de setembro de 2026 atualizado por: Assistance Publique Hopitaux De Marseille

A Comparative Historical-prospective "Before/After" Study Evaluating the Impact of Intensive Dietary Care on Weight Change and Biological Parameters in Patients Who Underwent Surgery for Craniopharyngioma During the First Postoperative Year

Craniopharyngiomas are rare benign tumors that develop in the hypothalamic-pituitary region. Their prevalence is estimated at approximately 1 in 50,000 people in France.

The main symptoms associated with this condition are headaches and visual, neurological, and hormonal disorders. These symptoms appear when the tumors are large enough to compress adjacent structures (optic chiasm, pituitary gland, etc.).

The current standard treatment is surgical removal via endonasal approach or craniotomy, most often combined with adjuvant radiotherapy. One of the common postoperative complications is significant and rapid weight gain leading to obesity, which occurs in 26 to 61% of cases depending on the type of surgery.

These disorders can cause impulsive eating, hyperphagia, and persistent hunger, leading to deleterious metabolic consequences with an increase in comorbidities (diabetes, cardiovascular disease, joint problems, abnormal blood tests, asthma, etc.). They can also have psychosocial consequences, with a significant risk of professional and personal activity cessation during the first year after surgery due to asthenia and other possible postoperative complications (dizziness, discomfort, etc.).

In addition, this surgery alters the functioning of the pituitary gland, requiring lifelong hormone supplementation, particularly with hydrocortisone, a hormone that is essential for stress management and energy release. The optimal doses for these replacement therapies are difficult to determine. They are most often found at the end of the first year after surgery, which can then allow for a gradual resumption of normal social and professional activities and better control of health and dietary advice. This first year after surgery is therefore a pivotal year in the possible development of obesity in these patients, which justifies the importance of intensive dietary care offered to these patients as early as possible.

The investigators hypothesise that intensive dietary care could prevent weight gain and an increase in comorbidities in patients who have undergone surgery for craniopharyngioma.

The primary objective of this study is to evaluate the impact of intensive dietary care (intervention group in a prospective phase) versus usual care (control group in a retrospective pre-intervention phase) on the relative weight change in patients one year after the first resection of a craniopharyngioma.

The primary endpoint is the relative change in weight at 1 year post-surgery, i.e. the difference between the weight recorded at the last dietary consultation 1 year post-surgery and that recorded at the preoperative consultation, relative to the weight recorded at the preoperative consultation.

This study is a comparative, quasi-experimental before/after study, with a pre-control phase corresponding to patients who have undergone surgery for their craniopharyngioma and have received standard dietary management versus an interventional 'after' phase, corresponding to patients who will undergo surgery for their craniopharyngioma and who will receive intensive dietary management. The study is single-centre, with 50 patients to be recruited in the control group and 25 in the intervention group.

The expected results are to assess whether intensive dietary care (versus standard care) can limit weight gain in the year following the first removal of a craniopharyngioma, as well as its impact on socio-professional activities and the onset of comorbidities.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

75

Estágio

  • Não aplicável

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Retrospective group:

    • Male or female patients aged between 18 and 70 (outside this age range, the BMI criteria are different).
    • Patients with craniopharyngioma who underwent initial craniopharyngioma resection surgery in Prof. Dufour's neurosurgery department at La Timone Hospital (APHM) between 1 January 2017 and 31 December 2021.
    • Weight data available at 15 days, 3 months and 1 year after their initial surgery in the Electronic Patient Record (EPR).
    • Patient informed and not opposed to the reuse of their data.
  • Prospective group:

    • Male or female patients aged between 18 and 70 (outside this age range, the BMI criteria are different).
    • Patients with craniopharyngioma in the immediate preoperative period of a first craniopharyngioma resection scheduled to be performed in Prof. Dufour's neurosurgery department at La Timone Hospital (APHM).
    • Patients affiliated with or covered by a social security scheme.
    • Patients who have signed a free, written and informed consent form.
    • Patients who have scales at home and are able to weigh themselves.

Exclusion Criteria:

  • - Retrospective group:

    • Patients with type 1 diabetes due to possible weight variation linked to a potential imbalance in diabetes.
    • Patients with a history of bariatric surgery, whose weight loss could be skewed by the surgical procedure (low food intake) and by changes in the secretion of the hormones leptin (satiety hormone) and ghrelin (hunger hormone), which are possible confounding factors.
    • Patients with recurrent craniopharyngioma who have a history of craniopharyngioma surgery or radiotherapy treatment for this tumour. These patients may already have hypothalamic disorders, eating disorders or weight gain following the initial removal of the craniopharyngioma.
    • Adult patients under guardianship or curatorship. Pregnant or breastfeeding women.
  • Prospective group:

    • Patients with memory disorders that prevent them from following dietary guidelines.
    • Patients with type 1 diabetes due to possible weight variation linked to a potential imbalance in diabetes.
    • Patients with a history of bariatric surgery, whose weight loss could be skewed by the surgical procedure (low food intake) and by changes in the secretion of the hormones leptin (satiety hormone) and ghrelin (hunger hormone), which are possible confounding factors.
    • Patients with recurrent craniopharyngioma who have a history of craniopharyngioma surgery or radiotherapy treatment for this tumour. These patients may already have hypothalamic disorders, eating disorders or weight gain following the initial removal of the craniopharyngioma.
    • Adult patients under guardianship or curatorship.
    • Pregnant or breastfeeding women.
    • Pregnancy (self-reported) or breastfeeding and all other categories of persons benefiting from special protection under the French Public Health Code (CSP): patients under legal protection, patients hospitalised without consent, patients admitted to social or health facilities for care and not for research, and patients in emergency situations.
    • Patients unable to give informed consent or who refuse to participate in the study.

Patient already participating in an interventional study on craniopharyngioma.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Retrospective group
Experimental: Prospective group

Intensive dietary care following surgery for a craniopharyngioma with 3 visits 2 weeks prior surgery, and 3 months after surgery associated with a follow up every 2 weeks over a year after surgery

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Relative weight change at 1 year post-surgery of a craniopharyngioma
Prazo: 1 year

Difference between the weight recorded at the last dietary consultation 1 year post-surgery and that recorded at the preoperative consultation, relative to the weight recorded at the preoperative consultation

1 year

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Relative weight change 15 days after surgery
Prazo: 15 days

Difference between the weight recorded during the dietary consultation 15 days after surgery and that recorded during the preoperative consultation, relative to the weight recorded during the preoperative consultation

15 days
Relative weight change 3 months after surgery
Prazo: 3 months

difference between the weight recorded during the dietary consultation 3 months after surgery and that recorded during the preoperative consultation, relative to the weight recorded during the preoperative consultation

3 months
Relative weight change 1 year after surgery
Prazo: 1 year

Difference between the weight recorded during the dietary consultation 1 year after surgery and that recorded during the preoperative consultation, relative to the weight recorded during the preoperative consultation

1 year
Absolute weight change 15 days after surgery
Prazo: 15 days

Difference between the weight recorded during the dietary consultation 15 days after surgery and that recorded during the preoperative consultation

15 days
Absolute weight change at 3 months post-surgery
Prazo: 3 months

the difference between the weight recorded during the dietary consultation 3 months post-surgery and that recorded during the preoperative consultation

3 months
Absolute weight change at 1 year post-surgery
Prazo: 1 year

the difference between the weight recorded during the dietary consultation 1 year post-surgery and that recorded during the preoperative consultation

1 year
Weight before surgery and then 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months and 1 year

Wheigh collecting on a weighing machine

15 days, 3 months and 1 year
Absolute change in BMI 15 days after surgery
Prazo: 15 days

difference between the BMI recorded during the dietary consultation 15 days after surgery and that recorded during the preoperative consultation

15 days
Absolute change in BMI 3 months after surgery
Prazo: 3 months

difference between the BMI recorded during the dietary consultation 3 months after surgery and that recorded during the preoperative consultation

3 months
Absolute change in BMI at 1 year after surgery
Prazo: 1 year

difference between the BMI recorded during the dietary consultation 1 year after surgery and that recorded during the preoperative consultation

1 year
Relative change in BMI 15 days after surgery
Prazo: 15 days

the difference between the BMI recorded during the dietary consultation 15 days after surgery and that recorded during the preoperative consultation, relative to that recorded during the preoperative consultation

15 days
Relative change in BMI at 3 months post-surgery
Prazo: 3 months

difference between the BMI recorded during the dietary consultation 3 months post-surgery and that recorded during the preoperative consultation, relative to that recorded during the preoperative consultation

3 months
Relative change in BMI at 1 year after surgery
Prazo: 1 year

the difference between the BMI recorded during the dietary consultation 1 year after surgery and that recorded during the preoperative consultation, relative to that recorded during the preoperative consultation

1 year
Percentage of patients who are overweight (BMI between 25 and 29.9 kg/m²) 15 days, 3 months and 1 year after surgery
Prazo: 15 days, 3 months and 1 year

Number of patients in each BMI category (Calculation of BMI according to Quetelet's formula) 15 days, 3 months and 1 year after surgery

15 days, 3 months and 1 year
Percentage of patients in each BMI category according to the World Health Organisation classification at 15 days, 3 months and 1 year after surgery
Prazo: 15 days, 3 months and 1 year

Number of patients in each BMI category according to the World Health Organisation classification (Calculation of BMI according to Quetelet's formula) at 15 days, 3 months and 1 year after surgery. Classification is as follow:

  • Normal: 18.5 to 24.9 kg/m²,
  • Overweight: 25 to 29.9 kg/m²,
  • Grade 1 obesity: 30 to 34.9 kg/m²,
  • Grade 2 obesity: 35 to 39.9 kg/m²,
  • Grade 3 obesity: 40 to 49.9 kg/m²,
  • Grade 4 obesity: > 50 kg/m²
15 days, 3 months and 1 year
Percentage of intermediate weight gain at each consultation
Prazo: 1 week or 15 days

Result of the calculation of divided the weight at today's consultation by the weight at the last consultation

1 week or 15 days
Percentage of patients presenting one or more biological abnormalities related to overweight or obesity (fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months, and 1 year

Number of patients presenting one or more biological abnormalities related to overweight or obesity (fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides)

15 days, 3 months, and 1 year
Percentage of patients with abnormal fasting blood glucose levels 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months, and 1 year

Number of patients with abnormal fasting blood glucose levels

15 days, 3 months, and 1 year
Percentage of patients with abnormal total cholesterol levels 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months, and 1 year

Number of patients with abnormal total cholesterol levels

15 days, 3 months, and 1 year
Percentage of patients with abnormal HDL cholesterol levels 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months, and 1 year

Number of patients with abnormal HDL cholesterol levels

15 days, 3 months, and 1 year
Percentage of patients with abnormal LDL cholesterol levels 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months, and 1 year

Number of patients with abnormal LDL cholesterol levels

15 days, 3 months, and 1 year
Percentage of patients with abnormal triglyceride levels at 15 days, 3 months, and 1 year after surgery
Prazo: 15 days, 3 months, and 1 year

Number of patients with abnormal triglyceride levels

15 days, 3 months, and 1 year
Change in quality of life compared to the preoperative dietary consultation, 15 days, 3 months and 1 year after surgery
Prazo: 15 days, 3 months and 1 year

Analysis of quality of life questionnaires (WHOQOL-BREF)

15 days, 3 months and 1 year
Total energy intake
Prazo: 15 days, 3 months and 1 year

Assessment of total energy intake calculated from dietary intake, including proteins, lipids and carbohydrates.Unit of Measure: kcal

15 days, 3 months and 1 year
Questionnaire on eating behaviour and feelings about food (DEBQ), pre-operatively, then 15 days, 3 months and 1 year after surgery
Prazo: 15 days, 3 months and 1 year

Analysis of the Dietary Behaviour and Eating Feelings Questionnaire (DEBQ)

15 days, 3 months and 1 year
Analysis of body composition (fat mass, lean mass) using an impedance meter (In Body device) 15 days, 3 months and 1 year after surgery
Prazo: 15 days, 3 months and 1 year

Impedance measurement

15 days, 3 months and 1 year

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de janeiro de 2027

Conclusão Primária (Estimado)

1 de abril de 2030

Conclusão do estudo (Estimado)

1 de julho de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

10 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de setembro de 2026

Primeira postagem (Real)

22 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • RCAPHM23_0030
  • ID RCB: 2024-A00186-41 (Outro identificador: ANSM)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever